Researchers design RNA therapy for thousands

Scientists at the University of Toronto and University Health Network have reported a new RNA-based approach aimed at a broad class of inherited disorders rather than a single mutation. In a paper published in *Science* on August 27, the team described chemically modified suppressor transfer RNAs, or sup-tRNAs, designed to read through premature stop signals in messenger RNA and restore production of full-length proteins. The work offers a clearer version of the claim circulating on X that researchers had designed an RNA therapy for “thousands” of diseases. The paper itself does not say the therapy treats all genetic diseases. It says nonsense mutations account for about 11% of human genetic diseases, and that suppressor tRNAs could be used across diseases that share the same stop-codon error. ### What exactly did the researchers build? (science.org) Jingan Chen, Bowen Li and co-authors engineered suppressor tRNAs, a class of RNA molecules whose anticodons were altered so they can read through premature termination codons, also known as nonsense mutations. Those mutations insert an early “stop” signal into an mRNA sequence, cutting off production of a working protein. The researchers then added defined chemical modifications to the tRNAs. (science.org) According to the *Science* summary, an N1-methyladenosine modification at position 57 or 58 improved performance, increasing readthrough by as much as 10.6-fold for one arginine suppressor tRNA, while also improving persistence and reducing innate immune activation. ### Why are “thousands” of diseases even in the conversation? The *Science* paper says nonsense mutations account for roughly 11% of human genetic diseases. (science.org) The University Health Network, describing the same study, said about 11% of genetic disorders are caused by mutations that prematurely halt the message encoded in DNA. That is the basis for broader claims that one platform could apply across many disorders, provided they share this mutation type. The University of Toronto said the approach has “potential to treat a wide range of genetic diseases that share certain disease-causing mutations.” That is narrower than saying one drug now works for all of them. It means the platform targets a recurring mutation mechanism, not every rare disease individually. ### Why did the team test it in cystic fibrosis? The researchers used cystic fibrosis as their disease model because nonsense mutations in the CFTR gene remain an unmet medical need, the *Science* summary said. (science.org) Cystic fibrosis provided a way to test whether the engineered tRNAs could restore production of a missing or truncated protein in a clinically relevant setting. University of Toronto and UHN said the study restored full-length protein production across laboratory and preclinical models of cystic fibrosis. (medicalxpress.com) The university also said the approach could be combined with existing cystic fibrosis drugs, suggesting a possible combination strategy in that disease first. ### How is this different from gene editing? (science.org) The *Science* paper says suppressor tRNAs act at the RNA level and do not alter genomic DNA. The authors contrasted that with gene-editing approaches, which they said can face delivery, immunogenicity and off-target challenges. That distinction matters because RNA therapies are reversible and transient. Reviews of RNA therapeutics describe that as one of the modality’s advantages, alongside reduced risk of permanent genomic integration. (pharmacy.utoronto.ca) ### What are the main limits from here? The August 27 paper is still preclinical. The *Science* summary and the university releases describe laboratory and animal-model results, not a late-stage human trial or an approved medicine. (science.org) Bowen Li’s faculty profile says the lab’s long-term goal is to establish programmable genetic medicines, and cites this work as a strategy for restoring protein production without permanently altering DNA. (pubmed.ncbi.nlm.nih.gov) The next steps are likely to center on delivery, durability and disease-specific testing before any clinical study. (pharmacy.utoronto.ca) (science.org)